Capricor Therapeutics Files 8-K on Shareholder Vote Matters

TL;DR

CAPR filed an 8-K for shareholder vote matters. Expect updates soon.

AI Summary

Capricor Therapeutics, Inc. filed an 8-K on May 15, 2024, reporting on a submission of matters to a vote of security holders. The filing date is May 15, 2024, with the earliest event reported on May 14, 2024. The company is incorporated in Delaware and its principal executive offices are located in San Diego, California.

Why It Matters

This filing indicates a formal process where shareholders will vote on specific company matters, which could impact corporate governance and future strategic decisions.

Risk Assessment

Risk Level: low — The filing is procedural and relates to a shareholder vote, not a direct financial event or significant operational change.

Key Players & Entities

• CAPRICOR THERAPEUTICS, INC. (company) — Registrant
• May 14, 2024 (date) — Earliest event reported
• May 15, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• San Diego, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital M

Filing Documents

• capr-20240514x8k.htm (8-K) — 59KB
• 0001558370-24-008310.txt ( ) — 174KB
• capr-20240514.xsd (EX-101.SCH) — 3KB
• capr-20240514_lab.xml (EX-101.LAB) — 15KB
• capr-20240514_pre.xml (EX-101.PRE) — 9KB
• capr-20240514x8k_htm.xml (XML) — 5KB

07

Item 5.07 Submission of Matters of a Vote of Security Holders. Capricor Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on May 14, 2024 at the Company's principal executive offices located at 10865 Road to the Cure, San Diego, California 92121. At the Annual Meeting, the Company's stockholders were asked to vote upon the following four proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 1, 2024. 1. The election of nine nominees to the Company's Board of Directors to serve until the 2025 annual meeting of stockholders. The nominees for election were Frank Litvack, M.D., Linda Marbn, Ph.D., David B. Musket, George W. Dunbar, Jr., Earl M. Collier, Jr., Karimah Es Sabar, Paul Auwaerter, M.D., Philip Gotwals Ph.D., and Michael Kelliher; 2. The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Rose, Snyder & Jacobs LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2024; 3. To approve, by non-binding advisory vote, the resolution approving named executive officer compensation; and 4. To approve an amendment to the Certificate of Incorporation to increase the number of authorized shares of the Company's common stock from 50,000,000 to 100,000,000. The final results of the matters voted on at the Annual Meeting, based on the presence in person or by proxy of holders of record of 21,324,236 shares of the 31,502,972 shares of the Company's common stock entitled to vote, were as follows: 1. Each of Frank Litvack, M.D., Linda Marbn, Ph.D., David B. Musket, George W. Dunbar, Jr., Earl M. Collier, Jr., Karimah Es Sabar, Paul Auwaerter, M.D., Philip Gotwals, Ph.D., and Michael Kelliher were elected as directors of the Company to serve until the 2025 annual meeting of stockholders, and until his or her successor is elected,

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CAPRICOR THERAPEUTICS, INC. Date: May 15, 2024 By: /s/ Linda Marbn, Ph.D. Linda Marbn, Ph.D. Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR